These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17163261)

  • 1. Pharmacokinetics of single oral doses of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers.
    Holdich T; Shiveley L; Sawyer J
    Clin Drug Investig; 2006; 26(5):279-86. PubMed ID: 17163261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of food on the pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor.
    Holdich T; Sawyer J
    Expert Opin Pharmacother; 2008 Aug; 9(12):2021-5. PubMed ID: 18671458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection.
    Cahn P; Rolon M; Cassetti I; Shiveley L; Holdich T; Sawyer J
    Clin Drug Investig; 2008; 28(2):129-38. PubMed ID: 18211121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Holdich T; Shiveley LA; Sawyer J
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2943-7. PubMed ID: 17242147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers treated with trimethoprim-sulphamethoxazole.
    Shiveley L; Struthers-Semple C; Cox S; Sawyer J
    J Clin Pharm Ther; 2008 Feb; 33(1):45-54. PubMed ID: 18211616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacokinetics of apricitabine in the presence and absence of ritonavir-boosted tipranavir: a phase I, open-label, controlled, single-centre study.
    Cox S; Southby J; Linet O; Tackwell K; Borin M; Perry K
    Clin Drug Investig; 2009; 29(11):721-8. PubMed ID: 19813775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.
    Cahn P; Cassetti I; Wood R; Phanuphak P; Shiveley L; Bethell RC; Sawyer J
    AIDS; 2006 Jun; 20(9):1261-8. PubMed ID: 16816554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racemate.
    Smith PF; Forrest A; Adams JM; Ballow CH
    J Clin Pharmacol; 2002 Jun; 42(6):658-61. PubMed ID: 12043954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro interactions between apricitabine and other deoxycytidine analogues.
    Bethell R; De Muys J; Lippens J; Richard A; Hamelin B; Ren C; Collins P
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2948-53. PubMed ID: 17517847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males.
    Smith PF; Forrest A; Ballow CH; Martin DE; Proulx L
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2816-23. PubMed ID: 10991865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.
    Cha YJ; Lim KS; Park MK; Schneider S; Bray B; Kang MC; Chung JY; Yoon SH; Cho JY; Yu KS
    Drug Des Devel Ther; 2014; 8():1613-9. PubMed ID: 25302016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.
    Wainberg MA; Cahn P; Bethell RC; Sawyer J; Cox S
    Antivir Chem Chemother; 2007; 18(2):61-70. PubMed ID: 17542150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the pharmacokinetics of abacavir.
    Yuen GJ; Weller S; Pakes GE
    Clin Pharmacokinet; 2008; 47(6):351-71. PubMed ID: 18479171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.